Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 20/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4819401 | 0.93 | CCR1 (0.62) | CCR1CYP2C19KCNH2 | |
| SCHEMBL4824445 | 0.86 | CCR1 (0.64) | CCR1CYP2C19KCNH2 | |
| SCHEMBL4818150 | 0.82 | CCR1 (0.54) | CCR1CYP2C19KCNH2 | |
| SCHEMBL4819061 | 0.79 | CCR1 (0.55) | CCR1CYP2C19KCNH2 | |
| SCHEMBL14566241 | 0.79 | CCR1 (0.64) | CCR1CYP2C19KCNH2 | |
| SCHEMBL4816268 | 0.79 | CCR1 (0.56) | CCR1CYP2C19KCNH2 | |
| SCHEMBL5360528 | 0.79 | CCR1 (0.58) | CCR1CYP2C19KCNH2 | |
| SCHEMBL14016489 | 0.79 | CCR1 (0.54) | CCR1CYP2C19KCNH2 | |
| SCHEMBL10291788 | 0.78 | CCR1 (0.72) | CCR1CYP2C19KCNH2 | |
| SCHEMBL4815084 | 0.78 | CCR1 (0.53) | CCR1CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435831-B2 | Bicyclic and bridged nitrogen heterocycles | CHEMOCENTRYX, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435831-B2 | Bicyclic and bridged nitrogen heterocycles | CHEMOCENTRYX, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435831-B2 | Bicyclic and bridged nitrogen heterocycles | CHEMOCENTRYX, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| WO-2007027734-A2 | BICYCLIC AND BRIDGED NITROGEN HETEROCYCLES | CHEMOCENTRYX, INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007027734-A2 | BICYCLIC AND BRIDGED NITROGEN HETEROCYCLES | CHEMOCENTRYX, INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20060074121-A1 | Bicyclic and bridged nitrogen heterocycles | CHEMOCENTRYX, INC. (US) | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074121-A1 | Bicyclic and bridged nitrogen heterocycles | CCR3, CCR1, CCR2 | CCR1 2/4885CYP2C19 2848/4885KCNH2 4515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.